Jylamvo (methotrexate) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): ____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION		
MEDICATUN	DISPENSING INFORMATION	

MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:	
		THERAPY/REFILLS:		
NEW THERAPY RENEWAL IF RENEWAL : DATE THERAPY INITIATED:				
DURATION OF THERAPY (SPECIFIC DATES):				
Continued on next page				

© 2024Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management - Commercial Clients. Revision Date: 2.1.2025 CAT009



Jylamvo (methotrexate) Prior Authorization Request Form Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MBER'S LAST NAME: MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY	OTHER MEDICATIONS FOR THIS	CONDITION?		
YES (if yes, complete below)	NO			
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
 Acute lymphoblastic leukemia (A Mycosis fungoids (cutaneous T-o Relapsed or refractory non-Hodo Rheumatoid Arthritis Severe psoriasis Other diagnosis: 	cell lymphoma) gkin lymphomas			
	ATION: PLEASE PROVIDE ALL REL	EVANT CLINICAL INFORMATION		
TO SUPPORT A PRIOR AUTHORI	as a part of the clinical trial?	es 🗌 No		
Acute lymphoblastic leukemia (ALL) Will Jylamvo be used as a part of a combination chemotherapy maintenance regimen? □ Yes □ No Relapsed or refractive non-Hodkin lymphoma Is Jylamvo being used as a part of a metronomic combination chemotherapy regimen? □ Yes □ No Does the patient have an enteral feeding tube? □ Yes □ No Does the patient have difficulty swallowing? □ Yes □ No Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other □ Yes				
information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.				
ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.				
Prescriber Signature or Electronic	c I.D. Verification:	Date:		
© 2024Prime Therapeutics Managen Prime Therapeutics Management – C				

Page 2 of 3

CAT009

Jylamvo (methotrexate) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: ____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

> **FAX THIS FORM TO:** 800-424-7640 MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

